Cronos Group has reached a settlement with $CRON investors over claims it inflated revenue through sham cannabis sales and hid major financial reporting weaknesses in 2019.
In 2019, Cronos reported strong revenue growth. But the company later restated its earnings after revealing that it had recorded non-existent sales from “round-trip” cannabis transactions. $CRON fell nearly 50% as the fraud came to light, and regulators launched investigations. After that, Cronos faced a lawsuit from investors.
May 9, 2019 – Cronos reported Q1 revenue that included C$2.5M in sales.
September 19, 2019 – An additional sale was booked with MediPharm, inflating Q3 revenue by C$3M.
February 24, 2020 – Cronos delayed its earnings release; $CRON fell 10.9%.
March 2, 2020 – The company filed an incomplete annual report; stock dropped 11.6%.
March 11, 2020 – Investors filed a lawsuit against Cronos.
March 30, 2020 – Cronos filed restatements for Q1 and Q3 2019 with internal control failures disclosed; $CRON dropped another 29%.
October 24, 2022 – The SEC and OSC charged Cronos and former executives with accounting fraud.
May 30, 2025 – Cronos agreed to settle the claims.
Cronos, a Canadian cannabis company, promoted itself as a leader in both medical and recreational cannabis markets. In 2019, it reported substantial revenue growth through deals with MediPharm and Heritage Cannabis.
But behind the scenes, Cronos recorded processing transactions as sales, falsely boosting revenue in at least two quarters.
In these round-trip arrangements, Cronos sent cannabis to be processed and then reacquired the product, yet booked the initial transfer as a sale.
These actions were later exposed, prompting earnings restatements for Q1 and Q3 2019, totaling a CAD $7.6 million reduction in revenue. The company also admitted internal control failures, and its auditor, KPMG, declined reappointment.
After all of this happened, in March 2020, shareholders sued the company for misleading them about its financial performance.
In 2022, U.S. and Canadian regulators charged Cronos and its former Chief Commercial Officer with accounting fraud.
Following the restatements and enforcement actions, $CRON dropped nearly 50% from its previous highs.
What Can Investors Expect Now?
Cronos Group has reached a settlement with $CRON investors over claims it inflated revenue through sham cannabis sales and hid major financial reporting weaknesses in 2019.
If you were damaged due to this situation, you can file for a payout and get your share of the settlement. You can check if you are eligible and other details in the FAQ section below.